INCY (Incyte Corporation) Net earnings per share growth this year

The 12-month earnings per share growth trend highlights the risks of dependence on a single flagship drug, with -53.50 representing the current level of the metric. US laboratories and patent protection ensure business stability. To diversify revenue, Incyte Corporation (INCY) is actively investing in dermatology and mergers to penetrate high-margin market segments.

The stability of Incyte Corporation (INCY) is based on the medical community's high level of trust in its innovative oncology drugs. This reputation converts into profit, which the metric measures through the percentage growth of net income per share relative to the previous year. By analyzing the EPS YoY trend, an investor can filter out market noise and determine whether the business is in a phase of fundamental growth or stagnation.